Literature DB >> 3149048

Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2.

M C Alessi1, I Juhan-Vague, T Kooistra, P J Declerck, D Collen.   

Abstract

Secretion of plasminogen activator inhibitor 1 (PAI-1) by cultures of human umbilical vein endothelial cells and human hepatocellular cell line Hep G2 was evaluated after insulin stimulation. The secretion of PAI-1 antigen and activity was measured in the conditioned medium and the cellular extracts after incubation of confluent cultures with 1% serum medium for 24 hours. Insulin induced a dose dependent increase of the PAI-1 secretion by Hep G2 cell line. At 10(-8) M a two fold increase of PAI-1 antigen and activity were observed whereas alpha 2 antiplasmin and fibrinogen were not significantly modified. No effect of insulin was observed on PAI-1 antigen and PAI activity production by human endothelial cells whereas endotoxin resulted in a two fold increase in PAI-1 secretion. In recent clinical studies we have demonstrated that the level of plasma insulin correlated with that of PAI-1. Thus we hypothesize that hepatocytes represent a physiological source of plasma PAI-1 which is modulated by plasma insulin level.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3149048

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  30 in total

1.  Prothrombotic markers in asymptomatic dyslipidemic subjects.

Authors:  David Karasek; Helena Vaverkova; Milan Halenka; Dagmar Jackuliakova; Zdenek Frysak; Ludek Slavik; Dalibor Novotny
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

2.  HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate.

Authors:  Mi-Hye Lee; Samar M Hammad; Andrea J Semler; Louis M Luttrell; Maria F Lopes-Virella; Richard L Klein
Journal:  J Lipid Res       Date:  2010-06-03       Impact factor: 5.922

3.  Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice.

Authors:  F Samad; D J Loskutoff
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

Review 4.  Exercise and diet in the prevention and control of the metabolic syndrome.

Authors:  R J Barnard; S J Wen
Journal:  Sports Med       Date:  1994-10       Impact factor: 11.136

Review 5.  Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.

Authors:  D de Bono
Journal:  Br Heart J       Date:  1994-06

6.  Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis.

Authors:  Mark M Smits; Pier Woudstra; Kristina M Utzschneider; Jenny Tong; Fernando Gerchman; Mirjam Faulenbach; Darcy B Carr; Kathryn Aston-Mourney; Alan Chait; Robert H Knopp; James B Meigs; Edward J Boyko; Steven E Kahn
Journal:  Ann Epidemiol       Date:  2013-03-25       Impact factor: 3.797

7.  Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

Authors:  A Asplund-Carlson; A Hamsten; B Wiman; L A Carlson
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

8.  Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.

Authors:  R P Gray; J S Yudkin; D L Patterson
Journal:  Br Heart J       Date:  1993-03

9.  Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans.

Authors:  P De Feo; M G Gaisano; M W Haymond
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

10.  Reduced carriership of 4G allele of plasminogen activator inhibitor-1 4G/5G polymorphism in very young survivors of myocardial infarction.

Authors:  Loukianos S Rallidis; Argyri Gialeraki; Efrosyni Merkouri; George Liakos; Nikolaos Dagres; Dimitrios Sionis; Anthi Travlou; John Lekakis; Dimitrios T Kremastinos
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.